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There is strong evidence that colorectal cancer survival differs between socioeconomic groups. We analysed data on 2481 patients
diagnosed during 1989–1997 and recruited to a randomised controlled clinical trial (AXIS, ISRCTN32414363) of chemotherapy and
radiotherapy for colorectal cancer. Crude and relative survival at 1 and 5 years was estimated in five categories of socioeconomic
deprivation. Multiple imputation was used to account for missing data on tumour stage. A multivariable fractional polynomial model
was fitted to estimate the excess hazard of death in each deprivation category, adjusting for the confounding effects of age, stage,
cancer site (colon, rectum) and sex, using generalised linear models. Relative survival in the trial patients was higher than in the general
population of England and Wales. The socioeconomic gradient in survival was much smaller than that seen for colorectal cancer
patients in the general population, both at 1 year  3.2% (95% CI  7.3 to 1.0%, P¼0.14) and at 5 years  1.7% (95% CI  8.3 to
4.9%, P¼0.61). Given equal treatment, colorectal cancer survival in England and Wales does not appear to depend on
socioeconomic status, suggesting that the socioeconomic gradient in survival in the general population could well be due to health-
care system factors.
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Cancer survival differs between socioeconomic groups (Kogevinas
and Porta, 1997; Woods et al, 2006). This has been demonstrated
for many adult cancers, including those of colon and rectum, both
in England and Wales (Coleman et al, 1999, 2001, 2004) and in
Scotland (Stockton, 2002; Shack et al, 2007). The origin of these
inequalities in survival remains largely unexplained and con-
troversial. Although late stage of disease at diagnosis is likely to
explain in part the lower survival among patients living in
deprived areas (Woods et al, 2006), in particular for colorectal
cancer (Mitry and Rachet, 2006), most recent research suggests
that other factors play an important role, such as differential access
to treatment or differential disease management by the health-care
system (Mitry and Rachet, 2006; Woods et al, 2006).
Clinical trials enable us to test the hypothesis that differential
treatment underpins the socioeconomic survival gradients in the
general population, because patients are randomly allocated into
treatment groups and all patients theoretically receive the same
treatment, with close adherence to protocol, regardless of their
socioeconomic status.
Our objective was to quantify socioeconomic differences in
survival among patients recruited to a randomised controlled trial.
We reasoned that if the socioeconomic gradient in survival was
abolished in the setting of a trial, with equal treatment for all
patients, then differences in treatment would become a more
plausible explanation for the socioeconomic differences in survival
as seen in the general population.
MATERIALS AND METHODS
The Medical Research Council (MRC) Clinical Trials Unit (CTU)
carried out a randomised clinical trial of adjuvant radiotherapy
and 5-fluorouracil (5-FU – a chemotherapy agent) infusion for
patients with colorectal cancer (AXIS trial, ISRCTN32414363). All
colon cancer patients and all but 60 of the rectal cancer patients
were randomised before or during surgery to postoperative portal
vein infusion (PVI) of 5-FU, or else no PVI. Half (49%) of the
rectal cancer patients were also randomised to radiotherapy or no
radiotherapy in a partial factorial design (Figure 1). A detailed
description has been published. No evidence of benefit was found,
either for PVI or for radiotherapy (The AXIS collaborators, 2003).
The AXIS trial began before the current system of Multi-Centre
Research Ethics Committees (MREC), although each participating
site had the appropriate local ethical approval. No REC was
prepared to evaluate the proposal to exploit the data from this trial
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from the ethics committee of the London School of Hygiene and
Tropical Medicine and from the independent AXIS Trial Steering
Committee, with support from the Chief Investigator.
The AXIS trial was designed to test whether 5-FU or radio-
therapy would improve overall and disease-free survival in patients
with resectable primary malignancy of the bowel. A total of 3681
patients met the initial eligibility criteria, namely the presence of
suspected colorectal adenocarcinoma and being fit to receive
radiotherapy and/or chemotherapy by PVI. Randomisation by
minimisation was used, stratified by cancer site (colon or rectum),
age, timing of radiotherapy and surgeon. This method ensures
balance between treatment groups for the specified factors (Pocock
and Simon, 1975).
Information on age, sex and tumour size was collected at
randomisation. Only data on modified Duke’s stage were available,
not tumour size.
A total of 3008 trial patients (82% of those originally
randomised) who were resident in England and Wales were
initially considered for analysis. We simplified follow-up by
excluding patients resident in Scotland or Northern Ireland
(257), as the Office for National Statistics (ONS) does not monitor
their vital status, and those who emigrated after diagnosis (25). A
further 204 patients were excluded as no ONS record could be
found, and 41 because of missing dates or postcode, or because the
cancer record had been cancelled. Postcode was required to assign
a deprivation category, and the dates of birth, diagnosis
(randomisation) and death are required to estimate survival by
age. We analysed data for 2481 patients: 1326 with colon cancer
and 1155 with rectal cancer (Table 1).
The AXIS trial patients were flagged on the National Health
Service Central Register to provide follow-up information on vital
status. The Office for National Statistics used the postcode of
residence at diagnosis to assign each patient a deprivation score on
the basis of the small area (electoral ward). For patients in
England, we used the ward Carstairs score (Carstairs, 1995) for
patients randomised during 1986–1995, and the ward income
domain score from the index of multiple deprivation (IMD) 2000
Randomised patients
(n=3681)
Patients records 
received
(n=3008)
Excluded from analysis (n=527)
• Have Scottishor Irish postcodes 
(n=257)
• Not on ONS records (n=204)
• Moved to Scotland or Ireland (n=25)
• Cancelled records (n=15)
• Duplicate trial number (n=1)
• Missing (n=25)
• date of birth
• date of randomisation
• deprivation
Analysed patients
(n=2481)
Colon
(n=1326) 
Rectum
(n=1155) 
Not randomised
(n=60)
No 5-FU
(n=544) 
5-FU
(n=551)
No 5-FU
(n=664) 
5-FU
(n=662) 
No radiotherapy
(n=34)
Radiotherapy
(n=26) 
No radiotherapy
(n=130) 
Radiotherapy
(n=133)
Not randomised
(n=281)
No radiotherapy
(n=120)
Radiotherapy
(n=122) 
Not randomised
(n=309) 
Data not supplied: not resident in  
England or Wales
(n=673)
Figure 1 Distribution of patients by cancer site (colon, rectum) and randomisation to postoperative portal vein infusion (PVI) of 5-fluorouracil (5-FU) or
radiotherapy (RT).
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for those randomised during 1996–1997. For patients in Wales, we
used the equivalent Welsh index. Patients were grouped into five
categories, from least deprived to most deprived, based on the
quintiles of the national distribution of scores for each ward
(Coleman et al, 2004). The Office for National Statistics supplied
anonymised data, including the deprivation category but not the
patient’s name, address, postcode or deprivation score, or the ward
from which it was derived.
Statistical analyses
All patients were followed up for at least 5 years to the end of 2003,
the last year for which complete information on vital status
was available. Survival was calculated in years as the interval
between the date of randomisation and the earliest of the date of
death, 31 December 2003 and the last date of follow-up, divided by
365.25. Survival probabilities were estimated 3-monthly for the
first 6 months, then at 1 year, annually up to 5 years and finally
at 7 years, using a maximum likelihood approach for individual
data (Este `ve et al, 1990). Relative survival was estimated
by deprivation category both for all patients and within each of
the two 5-FU trial arms. We report relative survival at 1 and
5 years.
Relative survival (Ederer et al, 1961) estimates the probability of
survival from the cancer by splitting the observed probability of
death into two components: the cancer-related and the background
probabilities of death. The background risk of death varies widely
by age, sex and socioeconomic group; we used deprivation-specific
life tables of all-cause mortality by single year of age at death, sex
and calendar period (Cancer Research UK Cancer Survival Group,
2004). These were derived from the number of deaths in three
successive calendar years, to provide a more robust estimation of
national death rates at each single year of age. The 1990–1992 life
tables were used to represent background mortality during 1986–
95, and the 1997–1999 life tables for 1996–2001.
Table 1 Number (%) of colorectal cancer patients by deprivation group
Deprivation category
Most affluent 2 3 4 Most deprived No of patients
Deprivation No. % No. % No. % No. % No. % No. %
(a) AXIS trial (1989–1997)
No. of patients 423 17.1 567 22.9 481 19.4 510 20.6 500 20.2 2481 100.0
Site of tumour
Colon 234 17.7 327 24.7 259 19.5 258 19.5 248 18.7 1326 53.5
Rectum 189 16.4 240 20.8 222 19.2 252 21.8 252 21.8 1155 46.6
Sex
Male 238 15.8 353 23.5 296 19.7 319 21.2 299 19.9 1505 60.7
Female 185 19.0 214 21.9 185 19.0 191 19.6 201 20.6 976 39.3
Age (years)
Less than 40 8 24.2 10 30.3 4 12.1 6 18.2 5 15.2 33 1.3
40–59 81 15.3 135 25.6 106 20.1 109 20.6 97 18.4 528 21.3
60–79 304 17.4 376 21.6 338 19.4 357 20.5 369 21.2 1744 70.3
80 and over 30 17.1 46 26.1 33 18.8 38 21.6 29 16.5 176 7.1
5-FU
No 217 18.0 279 23.1 223 18.5 240 19.9 249 20.6 1208 48.7
Yes 195 16.1 277 22.8 248 20.5 257 21.2 236 19.5 1213 48.9
Not randomised 11 18.3 11 18.3 10 16.7 13 21.7 15 25.0 60 2.4
Duke’s stage
A 56 19.2 68 23.3 59 20.2 59 20.2 50 17.1 292 11.8
B 171 17.5 226 23.2 201 20.6 194 19.9 183 18.8 975 39.3
C 117 15.2 181 23.5 137 17.8 165 21.5 169 22.0 769 31.0
D 44 21.4 44 21.4 37 18.0 45 21.8 36 17.5 206 8.3
Missing 35 14.6 48 20.1 47 19.7 47 19.7 62 25.9 239 9.6
(b) General population of England and Wales (1991–1995)
No. of patients 17800 14.3 21438 17.3 24826 20.0 28954 23.3 31229 25.1 124247 100.0
Site of tumour
Colon 11222 14.7 13555 17.7 15557 20.3 17650 23.0 18607 24.3 76591 61.6
Rectum 6578 13.8 7883 16.5 9269 19.5 11304 23.7 12622 26.5 47656 38.4
Sex
Male 9301 14.4 10951 17.0 12792 19.8 15003 23.2 16531 25.6 64578 52.0
Female 8499 14.2 10487 17.6 12034 20.2 13951 23.4 14698 24.6 59669 48.0
Age (years)
Less than 40 219 15.3 208 14.6 256 17.9 350 24.5 397 27.8 1430 1.2
40–59 3229 16.5 3430 17.5 3802 19.4 4368 22.3 4739 24.2 19568 15.8
60–79 10245 13.9 12584 17.0 14679 19.9 17205 23.3 19159 25.9 73872 59.5
80 and over 4107 14.0 5216 17.8 6089 20.7 7031 23.9 6934 23.6 29377 23.6
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estimated with variance-weighted linear regression as the fitted
difference between the ‘most affluent’ and ‘most deprived’
categories (Grizzle et al, 1969), and compared with the deprivation
gap for the general population of England and Wales (Coleman
et al, 2004). The gap is defined as negative if survival is lower in the
‘most deprived’ group.
Missing data
Tumour stage was the only variable with missing values (239
patients, 10%). Multiple imputation (Rubin, 1987; Schafer, 1997)
was used to account for this incompleteness. In this approach, a
model is posited for the association between missing values and
recorded values, using records in which stage data are available.
This model is used to generate several replicate ‘completed’ data
sets, containing imputed values in place of the missing values.
Estimates of the parameters of interest in each completed data set,
with their variance, are then pooled using multiple imputation
rules (Rubin, 1987). Ten imputations were performed: simulation
studies have shown no extra benefit from using more imputations
for variables with up to 50% missing values (Little and Rubin,
1987; Rubin, 1996).
Multivariable modelling using fractional polynomials
Multivariable regression using a generalised linear model with
Poisson error (Dickman et al, 2004) was used to estimate the excess
hazard of death of the trial patients over the background mortality.
We also estimated the excess hazard ratio (reference: most affluent
category) associated with deprivation, adjusting for the confounding
effects of age at randomisation, sex, cancer site (colon, rectum) and
stage. The fractional polynomials approach (Sauerbrei et al,1 9 9 9 )
was applied to each of the ten ‘completed’ data sets, to model
potentially non-linear relationships of both the baseline excess
hazard and the excess hazard ratio of the continuous prognostic
factors. The variables time since randomisation, stage, sex and
cancer site were forced into the model to adjust for the excess
mortality hazard of deprivation. The interactions between follow-up
time and deprivation or age were tested. The Akaike Information
Criterion (AIC) was used to measure the goodness of fit of each
model. All analyses were carried out using Stata algorithms
(StataCorp, 1997; Dickman, 2006).
RESULTS
The 2481 patients were more or less equally distributed across the
five deprivation categories in each of the main arms of the trial
(data not shown) and in both arms combined (Table 1). Over 90%
of patients were aged 40–79 years, 60.7% were male, and some
70% were diagnosed at Duke’s stage B or C. Data on stage were
missing for 9.6% of cases.
Across the five deprivation groups, relative survival ranged from
85.5 to 90.8% at 1 year after diagnosis and from 63.4 to 67.3% at 5
years (Table 2), but there was no evidence of a linear trend across
deprivation groups. As reported in the original trial, survival at 1
and 5 years was similar in both arms of the trial (5-FU or not; data
not shown).
For all patients combined, the fitted difference in survival
between the most affluent and most deprived groups was  3.2% 1
year after diagnosis and  1.7% after 5 years; neither result was
statistically significant (Table 2, Figure 2). The deprivation gap in
survival at 1 and 5 years was smaller than that estimated in the
general population of England and Wales for the calendar period
1991–1995, during which 80% of the trial patients were diagnosed.
Results were similar when each trial arm was examined separately
(data not shown).
The final model of the excess hazard ratio, after imputation of
missing values for stage, included age, stage and site, as well as
time since randomisation and deprivation category. The excess
hazards for age and deprivation remained proportionate by time
since randomisation.
The excess hazard of death within 5 years after diagnosis was
between 9 and 20% higher in more deprived categories than in the
most affluent group, after adjustment for time since randomisa-
tion, age, sex, cancer site and stage. The effect was not linear, and
the overall effect of deprivation on the excess hazard of death was
not statistically significant (Table 3). The excess hazard of death
increased with tumour stage and, to a lesser extent, with age at
randomisation. Rectal cancer patients and men both experienced a
higher excess hazard of death.
DISCUSSION
Population studies have shown that the survival of colorectal
cancer patients varies by deprivation category. By contrast, there
Table 2 Relative survival (%) by deprivation category and deprivation
gap (%) at 1 and 5 years: AXIS study population (diagnosed 1989–1997)
and general population of England and Wales (1991–1995)
Study population General population
Colon Rectum
Patients Deaths
Relative
survival
Relative
survival
1-year survival
Most affluent 423 52 90.8 67.2 73.2
2 567 98 85.5 65.4 72.5
3 481 71 88.6 65.1 71.0
4 510 85 87.2 63.6 69.8
Most deprived 500 86 86.0 61.6 68.8
Deprivation gap (%) 3.2  5.3
a  4.6
a
5-year survival
Most affluent 423 186 66.7 45.0 45.0
2 567 251 64.5 44.3 45.3
3 481 205 67.3 43.2 44.0
4 510 241 63.4 42.1 41.7
Most deprived 500 238 65.0 39.6 39.4
Deprivation gap (%)  1.7  5.3
a  6.3
a
aStatistically significant at 1%.
AXIS data
England & Wales, 1991–1995
40
50
60
70
80
90
100
R
e
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
 
(
%
)
0 1 2 3 4 5
Time since diagnosis (years)
Most affluent
2
3
4
Most deprived
Figure 2 Relative survival (%) at 1 and 5 years, by deprivation category,
in the AXIS trial (1989–97) and the general population of England and
Wales (1991–1995).
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scale trial, either at 1 or 5 years after randomisation. There was no
evidence of a deprivation gradient in the excess hazard of death
after adjustment for time since randomisation, age, sex, tumour
site and stage.
The AXIS study is one of the largest randomised trials of
treatment for colorectal cancer (3681 patients). Detailed informa-
tion on stage at diagnosis and treatment was available for 2481
patients who were randomised and could be followed up for at
least 5 years in England and Wales. Random allocation and
adherence to protocol ensured that all patients in a given arm
followed similar treatment policies, regardless of socioeconomic
status. Indeed, socioeconomic status as defined for this study was
not known to the AXIS investigators or clinicians at the time: it
was only derived after the trial, from the postcode of residence at
diagnosis.
One- and 5-year survivals were much higher (13–25%) than
among colorectal cancer patients in England and Wales in the
same period (see Table 2) (Coleman et al, 1999). At first sight, this
supports the view that cancer patients taking part in clinical trials
get better treatment and have higher survival than the average
population of cancer patients (Lara et al, 2001), but patients in the
AXIS trial were younger than colorectal cancer patients in general.
Higher survival was also expected, as most trial patients had early-
stage, resectable disease. More important, there was no evidence of
a deprivation gap in survival in the AXIS trial. This contrasts
markedly with the significant deprivation gap in colorectal cancer
survival at 1 and 5 years among patients diagnosed in England and
Wales during 1991–1995.
If bias in selection for treatment could be ruled out, the results
of this study suggest that the origin of the deprivation gradient in
survival in the general population lies either in later diagnosis
among more deprived patients or in socioeconomic differences in
access to optimal treatment.
The socioeconomic gradients in 1- and 5-year survival in the
AXIS study were small and not statistically significant. The
survival gradients lie outside the 95% confidence intervals around
the corresponding estimates for the general population of England
and Wales (Coleman et al, 1999, 2001). Even in this large study,
however, statistical power was limited, given the relatively small
number of deaths in each deprivation group. We imputed missing
values for tumour stage to minimise loss of power.
Stage at diagnosis and tumour site (colon or rectum) are both
highly significant prognostic factors in colorectal cancer. The
results confirm this, but adjustment for these factors had little
impact on the excess hazard ratio in each socioeconomic group.
Data from both arms of the trial were merged: this was justified
because neither treatment had an impact on the excess hazard of
death, which corroborates the main result of the AXIS trial (The
AXIS collaborators, 2003).
The absence of a deprivation gradient in survival within this
clinical trial suggests that lower survival among deprived patients
in the general population may be due to health-care factors, such
as delay in diagnosis, inequality in the thoroughness of diagnostic
investigation or unequal access to optimal treatment. It could be
argued that fewer patients were included from deprived groups
than from affluent groups on the grounds of severe comorbidity
that might have prevented treatment or led to the interruption of
treatment because of adverse effects. Such differences might
explain lower survival among deprived patients in the general
population. In the AXIS trial, however, the socioeconomic
distribution of patients was unknown at randomisation. The
percentage of patients treated in the most deprived group in the
trial was slightly lower than the comparable group of colorectal
cancer patients in the general population, but the socioeconomic
distribution of AXIS trial patients was still weighted toward the
more deprived groups. These points argue against selection bias in
the AXIS trial arising from preferential recruitment of more
affluent patients on the grounds of lower comorbidity.
In the USA, survival was similar among blacks and whites in
trials of adjuvant therapy for colon cancer (Dignam et al, 1999).
One commentator remarked that race in the USA is a surrogate for
socioeconomic status, adding, ‘Ultimately (this result) helps one
understand that equal treatment yields equal outcome among
patients with the same stage of disease, regardless of race’ (Brawley
and Freeman, 1999). In similar vein, the findings from the AXIS
study tend to suggest that equal treatment does yield equal
outcome, regardless of socioeconomic status.
We can conclude that, given equal treatment at a given stage of
disease, survival from colorectal cancer does not depend on
socioeconomic status. This supports the notion that health-care
system factors do underpin inequalities in survival in the general
population. However, our study cannot determine directly whether
inequalities in survival are due to differences in access to optimal
treatment. We plan similar analyses of patients randomised in four
other large trials, two of ovarian cancer and two of testicular cancer.
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